NAS:MLTX (Switzerland)
Â
Class A
$
42.43
-0.82 (-1.9%)
10:08 PM EST
Business Description
MoonLake Immunotherapeutics
NAICS : 541720
SIC : 2833
ISIN : KY61559X1045
Share Class Description:
MLTX: Class ADescription
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. The company derives maximum revenue from United Kingdoms.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 134.26 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.42 | |||||
| 9-Day RSI | 36.51 | |||||
| 14-Day RSI | 37.09 | |||||
| 6-1 Month Momentum % | -2.18 | |||||
| 12-1 Month Momentum % | 117.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 51.59 | |||||
| Quick Ratio | 51.59 | |||||
| Cash Ratio | 51.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -0.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -11.99 | |||||
| ROA % | -10.74 | |||||
| ROIC % | -1215.38 | |||||
| ROC (Joel Greenblatt) % | -5373.71 | |||||
| ROCE % | -16.56 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 5.17 | |||||
| Price-to-Tangible-Book | 5.17 | |||||
| EV-to-EBIT | -40.87 | |||||
| EV-to-EBITDA | -40.88 | |||||
| EV-to-Forward-Revenue | 30.21 | |||||
| EV-to-FCF | -51.71 | |||||
| Price-to-Net-Current-Asset-Value | 5.31 | |||||
| Price-to-Net-Cash | 5.34 | |||||
| Earnings Yield (Greenblatt) % | -2.45 | |||||
| FCF Yield % | -1.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MLTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MoonLake Immunotherapeutics Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.74 | ||
| Beta | 0 | ||
| Volatility % | 101.91 | ||
| 14-Day RSI | 37.09 | ||
| 14-Day ATR ($) | 2.075868 | ||
| 20-Day SMA ($) | 45.2985 | ||
| 12-1 Month Momentum % | 117.94 | ||
| 52-Week Range ($) | 19.8 - 64.98 | ||
| Shares Outstanding (Mil) | 62.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MoonLake Immunotherapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MoonLake Immunotherapeutics Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
MoonLake Immunotherapeutics Frequently Asked Questions
What is MoonLake Immunotherapeutics(MLTX)'s stock price today?
The current price of MLTX is $42.43. The 52 week high of MLTX is $64.98 and 52 week low is $19.80.
When is next earnings date of MoonLake Immunotherapeutics(MLTX)?
The next earnings date of MoonLake Immunotherapeutics(MLTX) is 2024-05-10 Est..
Does MoonLake Immunotherapeutics(MLTX) pay dividends? If so, how much?
MoonLake Immunotherapeutics(MLTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers